Featured Research

from universities, journals, and other organizations

Ability to ride a bike can aid differential diagnosis of Parkinson's disease in any setting

Date:
October 7, 2011
Source:
IOS Press
Summary:
Researchers report that the ability to ride a bike can differentiate between atypical parkinsonism and Parkinson's disease, regardless of the environment or situations for bicycling.

In a new study published October 6 in the Journal of Parkinson's Disease, Japanese researchers report that the ability to ride a bike can differentiate between atypical parkinsonism and Parkinson's disease, regardless of the environment or situations for bicycling.

Atypical parkinsonisms are disorders that look similar to Parkinson's disease, but respond differently to treatments. The "bicycle sign" can help clinicians differentiate between the two. Patients with atypical parkinsonism lose their ability to cycle during the early phase of the illness, while patients with Parkinson's disease continue to ride well. Actual environments or situations for biking differ from one country to another, raising the question of whether the "bicycle sign" could be universally applicable. Hideto Miwa and Tomoyoshi Kondo, of the Department of Neurology at Wakayama Medical University, in Wakayama, Japan, set out to determine if the "bicycle sign" would be reliable in Japan, where the roads are hilly, narrow, and crowded with automobiles.

The study found that 88.9% of Japanese patients with atypical parkinsonism had ceased bicycling during the few years around the onset of their illness, as compared with only 9.8% of the patients with Parkinson's disease. In fact, the prevalence of the "bicycle sign" may be much higher in Japan than in The Netherlands (51.5%), which is known as one of the world's most bicycle-friendly countries. This may be because the tough bicycle environment in Japan makes it more difficult for atypical parkinsonism patients to bike.

"Although bicycling cultures may differ between countries, it is possible that the 'bicycle sign' could contribute to earlier and better differential diagnosis of parkinsonism during the diagnostic interview. When we see patients with parkinsonism without a definitive diagnosis, it is a simple thing to ask the question, 'Can you still ride a bicycle?'" commented Dr. Miwa.


Story Source:

The above story is based on materials provided by IOS Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hideto Miwa and Tomoyoshi Kondo. Bicycle Sign for Differential Diagnosis of Parkinsonism: Is It of Use in a Hilly Country Like Japan? Journal of Parkinson's Disease, 1(2) DOI: 10.3233/JPD-2011-11039

Cite This Page:

IOS Press. "Ability to ride a bike can aid differential diagnosis of Parkinson's disease in any setting." ScienceDaily. ScienceDaily, 7 October 2011. <www.sciencedaily.com/releases/2011/10/111006184204.htm>.
IOS Press. (2011, October 7). Ability to ride a bike can aid differential diagnosis of Parkinson's disease in any setting. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/10/111006184204.htm
IOS Press. "Ability to ride a bike can aid differential diagnosis of Parkinson's disease in any setting." ScienceDaily. www.sciencedaily.com/releases/2011/10/111006184204.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins